Daily Cardiology Research Analysis
Analyzed 166 papers and selected 3 impactful papers.
Summary
Analyzed 166 papers and selected 3 impactful articles.
Selected Articles
1. 1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.
In this multicenter randomized trial of AF patients undergoing PCI with imaging guidance, 1-month DOAC+P2Y12 followed by DOAC monotherapy was non-inferior to 12 months for death or thromboembolism and significantly reduced major or clinically relevant non-major bleeding at 12 months. Net clinical benefit favored the shorter strategy, though efficacy estimates warrant caution due to low event rates.
Impact: Provides high-quality randomized evidence to safely shorten dual antithrombotic therapy after AF-PCI, addressing a key bleeding–ischemia trade-off question.
Clinical Implications: For AF patients undergoing PCI with intravascular imaging guidance, clinicians can consider 1-month DOAC+P2Y12 followed by DOAC monotherapy to reduce bleeding while maintaining efficacy, with careful patient selection and monitoring.
Key Findings
- 1-month DOAC+P2Y12 followed by DOAC monotherapy was non-inferior to 12 months for death or thromboembolic events at 12 months.
- Major or clinically relevant non-major bleeding was reduced with the 1-month strategy.
- Trial enrolled 1,079 patients at 75 Japanese sites with intravascular imaging-guided PCI; event rates were lower than anticipated.
Methodological Strengths
- Multicenter randomized controlled design with active comparator
- Intravascular imaging-guided PCI enhances procedural standardization
Limitations
- Open-label design may introduce performance or detection bias
- Lower-than-anticipated event rates and fixed absolute non-inferiority margin impact precision of efficacy estimates
Future Directions: Prospective implementation studies across diverse populations and care settings, with cost-effectiveness and imaging-guided criteria refinement, to confirm generalizability and optimize patient selection.
BACKGROUND: The optimal duration of dual antithrombotic therapy after percutaneous coronary intervention (PCI) in patients with atrial fibrillation remains uncertain. We aimed to compare the efficacy and safety of 1-month versus 12-month dual antithrombotic therapy in this population. METHODS: OPTIMA-AF was an active-control, randomised, hybrid non-inferiority and superiority trial in which patients with atrial fibrillation undergoing PCI with intravascular imaging guidance were randomly assigned (1:1) to receive 1-month dual antithrombotic therapy (direct oral anticoagulant [DOAC] plus P2Y12 inhibitor) followed by DOAC monotherapy or 12-month dual therapy followed by DOAC monotherapy, across 75 sites in Japan. Eligible patients were aged 20 years or older with non-valvular atrial fibrillation, a CHADS FINDINGS: From Oct 7, 2019, to Sept 3, 2024, 1101 patients were assessed for eligibility; 1088 were randomly assigned to treatment and 1079 were included in the full analysis set (1-month dual therapy n=542; 12-month dual therapy n=537). Median age was 76 years (IQR 70-81). 225 (21%) of 1079 patients were female and 854 (79%) were male. Median CHADS INTERPRETATION: Among patients with atrial fibrillation and predominantly chronic coronary syndrome undergoing PCI with intravascular imaging guidance, 1-month dual antithrombotic therapy followed by DOAC monotherapy was non-inferior to 12-month therapy for death or thromboembolic events and reduced major or clinically relevant non-major bleeding at 12 months, suggesting an overall favourable net clinical profile. Efficacy findings should be interpreted with appropriate caution in light of the lower-than-anticipated event rates and fixed absolute non-inferiority margin. FUNDING: Abbott Medical Japan. TRANSLATIONS: For the Japanese translation of the abstract see Supplementary Materials section.
2. A NETwork meta-analysis with COST-effectiveness evaluation of pharmacological treatments for Heart Failure with Reduced Ejection Fraction: NET-COST-HFrEF.
Across 47 RCTs (N=75,978), increasing use of guideline-directed therapies reduced all-cause mortality and HF hospitalizations. Decision analytic modeling showed ARNI+beta-blocker+MRA+SGLT2 inhibitor quadruple therapy to be the most cost-effective regimen in the UK base case, with consistent findings in Sweden and the US.
Impact: Provides robust comparative- and cost-effectiveness evidence supporting early adoption of quadruple therapy in HFrEF, informing payers and guideline implementers.
Clinical Implications: Prioritize early initiation of quadruple therapy (ARNI+BB+MRA+SGLT2i) when tolerated; use these findings to support reimbursement and implementation strategies across health systems.
Key Findings
- Included 47 RCTs with 75,978 patients; increasing number of HFrEF therapies reduced all-cause mortality and HF hospitalizations.
- Quadruple therapy (ARNI+BB+MRA+SGLT2i) was the most cost-effective strategy in the UK base case (12.31 QALYs; net monetary benefit £338,460).
- Cost-effectiveness rankings were consistent in scenario analyses using Sweden and US healthcare perspectives.
Methodological Strengths
- Random-effects network meta-analysis of RCTs with large aggregate sample size
- Decision tree–Markov model populated with trial efficacy, quality-of-life, and multi-country cost data
Limitations
- Heterogeneity across trials and assumptions inherent to network meta-analysis and economic modeling
- Primary cost inputs based on UK perspective; transferability depends on local pricing and implementation feasibility
Future Directions: Prospective implementation studies and pragmatic trials to evaluate real-world uptake, adherence, equity, and budget impact of quadruple therapy; head-to-head comparisons of sequencing and titration strategies.
BACKGROUND AND AIMS: To assess the cost-effectiveness of guideline-directed medical treatments for heart failure with reduced ejection fraction (HFrEF) by performing a network meta-analysis (NMA) of randomized controlled trials (RCTs) feeding a subsequent cost-effectiveness analysis. METHODS: A random-effects NMA of RCTs was conducted. The primary analysis included only RCTs evaluating drugs in the clinical settings as recommended in the 2021 European Society of Cardiology HF guidelines. Main efficacy outcomes included all-cause mortality (ACM) and total HF hospitalizations (HFH). A decision tree-Markov model was populated with NMA-derived efficacy estimates, quality-of-life data, and costs from United Kingdom (UK, main analysis), as well as Sweden and United States (US) (scenario analyses) healthcare perspectives. RESULTS: 47 RCTs (75,978 patients) were included. The risk of ACM and total HFH decreased with increasing number of pharmacological treatments. In the main (UK) analysis, the greatest benefit was observed with a quadruple therapy including angiotensin receptor-neprilysin inhibitor (ARNI) + β-blocker (BB) + mineralocorticoid receptor antagonist (MRA) + sodium-glucose cotransporter 2 inhibitors (SGLT2i), which resulted as the most cost-effective strategy (12.31 quality-adjusted life-years; net monetary benefit of £338,460; UK perspective). Findings were consistent in Sweden and US. CONCLUSION: Quadruple therapy with ARNI+BB+MRA+SGLT2i had the highest probability of being the most cost-effective strategy. Our findings might inform future health economic policies and reimbursement decisions, while also considering affordability, budget impact, and implementation feasibility.
3. Catheter ablation of atrial fibrillation in patients with heart failure: a trial-level meta-analysis.
Pooling 13 RCTs (n=2,490), catheter ablation for AF in heart failure reduced all-cause mortality (HR 0.58) and cardiovascular death (HR 0.52), lowered HF/AF-related adverse events, and improved LVEF and quality of life compared with guideline-recommended pharmacological therapy alone.
Impact: Demonstrates mortality reduction with ablation in HF+AF beyond symptom control, supporting earlier rhythm-control strategies in appropriate candidates.
Clinical Implications: Consider catheter ablation earlier in HF patients with AF after multidisciplinary evaluation; anticipate greater benefit in selected populations while acknowledging limited data in HFpEF and older/high-risk groups.
Key Findings
- Across 13 RCTs (n=2,490), catheter ablation reduced all-cause mortality (HR 0.58; 95% CI 0.44-0.76) and cardiovascular death (HR 0.52; 95% CI 0.36-0.74).
- Ablation improved LVEF by +6% and MLWHFQ by -12 points, with a trend toward better 6-minute walk distance.
- Most trials were unblinded, predominantly male (<65 years), and few evaluated HFpEF, highlighting generalizability limits.
Methodological Strengths
- Trial-level meta-analysis restricted to randomized controlled trials
- Consistent effects across mortality, functional, and quality-of-life outcomes
Limitations
- Predominantly unblinded trials with patient selection favoring younger males; limited HFpEF data
- Potential heterogeneity in ablation techniques and background medical therapy across trials
Future Directions: Pragmatic RCTs including older and high-comorbidity patients; head-to-head comparisons of ablation strategies; cost-effectiveness and equity analyses.
INTRODUCTION: Many patients with heart failure (HF) have or develop atrial fibrillation (AF), which may contribute to worsening symptoms, hospitalisations and mortality. Whether catheter ablation improves outcomes in patients with HF and AF receiving guideline-recommended pharmacological therapy (GRPT) is controversial. AIMS: A systematic review and meta-analysis of relevant randomised controlled trials (RCT)s on the role of catheter ablation in patients with AF and HF. METHODS: Public databases for trials published prior to 17th March 2025 and investigating the effects of catheter ablation on morbidity and mortality in patients with HF and AF were searched. Outcomes of interest were all-cause and cardiovascular mortality, adverse events due to HF or AF, changes in left ventricular ejection fraction (LVEF), 6-Minute Walking Distance (6-MWD) and Minnesota Living With Heart Failure Questionnaire (MLWHFQ) scores. RESULTS: Altogether, thirteen RCTs including 2,490 patients (predominantly aged <65 years; of whom 73% were men and 79% reported persistent AF) were identified. Blinding of intervention was not attempted. Only three RCTs assessed the effect of catheter ablation in patients with preserved LVEF. Overall, compared to GRPT alone, catheter ablation was associated with lower all-cause mortality (hazard ratio [HR]: 0.58; 95% confidence interval [CI]: 0.44-0.76), cardiovascular death (HR: 0.52; 95% CI: 0.36-0.74) and adverse events related to HF or AF (HR: 0.69; 95% CI: 0.53-089). In addition, catheter ablation improved LVEF (+6% mean difference (MD)[95% CI: +4% to +9%]) and MLWHFQ (-12 points MD [95% CI: -18 points to -6 points]), with a trend to enhanced 6-MWD (+18 meters MD [95% CI: -1 meter to +38 meters]). CONCLUSIONS: For a selected group of patients with chronic HF and AF enrolled in un-blinded RCTs, catheter ablation improved cardiac function, wellbeing and outcomes, including all-cause mortality. Further RCTs are required to determine whether the benefits of catheter ablation extend to a broader population of patients at higher risk of procedural failure and recurrent AF.